Hong Kong processed 698 initial public offering applications through May 29, with 500 applications still under review, according to a monthly report released by Hong Kong Exchanges and Clearing (HKG:0388) on Friday.
Hong Kong recorded 62 new listings year-to-date, with all but one on the main board. On the flip side, 22 companies delisted during the period.
The number of listed companies stood at 2,726 as of May 29, up from 2,686 at the start of the year, data showed.
Chongqing Genrix Biopharmaceutical (SHA:688443) granted C.Q. Pharmaceutical (SHE:000950) subsidiary Yaoyou Pharmaceutical exclusive development and distribution rights for the GR1803 drug across China and Hong Kong, Macau, and Taiwan.The agreement covers development such as clinical trials, research, and manufacturing, as well as sales, the filing said.The GR1803 velitumimumab drug is indicated for multiple myeloma, a rare form of blood cancer.Yaoyou will pay Genrix up to 600 million yuan in initial payment, listing milestone, and technology transfer milestone payments.Genrix will also be eligible to receive sales royalties of up to a minimum percentage of two digits.
Xuan Wu Cloud Technology's (HKG:2392) Chief Financial Officer Ge Ping resigned to devote more time to personal affairs effective May 31, according to a Friday Hong Kong bourse filing.
Xi'an Eswin Materials Technology (SHA:688783) will invest up to 40 million yuan in a pre-A+ funding round for Zhuhai Yiyuan Technology, according to a Friday filing with the Shanghai bourse.Zhuhai Yiyuan Technology seeks to raise between 100 million yuan and 200 million yuan in a funding round.The glass manufacturer plans to use the proceeds for capacity expansion, equipment procurement, and technology upgrades.